CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.7% - Here's What Happened

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s share price traded down 1.7% during trading on Tuesday . The stock traded as low as $40.52 and last traded at $41.55. 799,523 shares changed hands during trading, a decline of 65% from the average session volume of 2,291,081 shares. The stock had previously closed at $42.29.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Citigroup dropped their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research report on Tuesday, February 18th. HC Wainwright reiterated a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. TD Cowen upgraded shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price for the company in a research report on Wednesday, February 12th. Royal Bank of Canada lowered their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group lowered their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating for the company in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $73.11.

Remove Ads

CRISPR Therapeutics Trading Up 5.1 %

The stock's 50 day moving average is $42.79 and its two-hundred day moving average is $45.79. The stock has a market capitalization of $3.91 billion, a price-to-earnings ratio of -10.42 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, Director John Greene bought 7,000 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The stock was acquired at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the purchase, the director now owns 7,000 shares of the company's stock, valued at approximately $313,950. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company's stock, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.10% of the company's stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the company. Wood Tarver Financial Group LLC acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at about $30,000. Wilmington Savings Fund Society FSB bought a new position in CRISPR Therapeutics in the 3rd quarter valued at about $40,000. Ameriflex Group Inc. acquired a new stake in CRISPR Therapeutics during the fourth quarter worth approximately $36,000. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics during the third quarter worth approximately $43,000. Finally, Highline Wealth Partners LLC acquired a new stake in CRISPR Therapeutics during the fourth quarter worth approximately $39,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.